



Nutrigenetic effects in metabolic syndrome – A cornerstone for individualized therapy

Nutritional therapy is the basis of antidiabetic treatment. It allows early remission, preserves residual metabolic functions beyond glycaemic control, counteracts polypharmacy and saves monetary resources.

The effectiveness of nutritional therapy is currently limited – due to moderate compliance with respect to many dietary approaches and lack of continuous consulting support under real-world conditions, but also due to sparse knowledge about high-risk phenotypes and possibilities of response prediction. One of the most prominent levers to improve the effectiveness of nutritional therapy are nutrigenetics. Several recent publications have demonstrated, that a specific dietary intervention may elicit extraordinary effects in certain genetic subgroups of patients. These findings cover the entire range of disorders within the Metabolic Syndrome: overweight and obesity (TCF7L2,^{1–3} FTO,⁴ DRD2^{5,6}), glucose intolerance, insulin resistance and hyperinsulinemia (ACE,⁷ FABP2,⁸ TCF7L2⁹), hypertension (ACE¹⁰), hyperuricemia (SLC2A9¹¹), hypertriglyceridemia (AT1R,¹² APOE,¹³ FABP2¹⁴), dyslipidemia (FABP2,^{15,16} FABP4¹⁷), elevated free fatty acids (FABP2¹⁸) and hypercholesterolemia (PPARGC1A,¹⁹ ADRB2,²⁰ APOE²¹). There is even evidence for nutrigenetic effects on possible long-term outcomes such as impaired cognition (VEGF, GLUT1²²) and all-cause mortality (OGG1²³). However, only few studies are interventional, limiting their reproducibility in controlled settings, which ensure compliance to a very specific dietary pattern.

The following publication adds another piece to the huge puzzle of nutrigenetics, presenting a dietary RCT in a larger, well-selected cohort, capable to answer a nutrigenetic hypothesis. The paper indicates that carriers of the rs670 ApoA1 A+ polymorphism – covering about 30% of the subjects – primarily show higher HDL levels. Additionally, they not only preserved, but increased their HDL levels by almost 10%, when undergoing a low-fat diet. The effect is specific to HDL and is not accommodated by possibly detrimental effects on other cardiometabolic parameters.

By comparison of low-fat and low-carb diet, the authors are able to demonstrate the relevance of this finding in the wider context of prediabetic dyslipidemia. In the hypocaloric setting, low-carb diets often result in stronger improvements of triglyceride levels, similar benefit with respect to LDL and better preservation of HDL. This well-known

pattern is replicated in the present trial, weakening the global relevance of HDL increase under low-fat conditions as the concomitant LDL improvement was limited. However, given the plethora of metabolic and behavioral patterns in subjects with prediabetes or overt T2DM, the present finding is a necessary step to individualize dietary recommendations. Subjects with the ApoA1 A+ genotype and with personal preference for a low-fat diet or contraindications for a low-carb approach (gout, renal impairment, chronic inflammatory disease) could benefit from increasing HDL without parallel impairment of other parameters.

A single SNP won't make a huge difference, but further investigations in the field of nutrigenetics need to be stimulated in order to provide wide-range knowledge on the interaction of genes and specific dietary interventions beyond mere weight loss. As this paper is the first nutrigenetic publication on rs670 in ApoA1 and one of the first on HDL, replication studies are needed. However, there are plenty of dietary RCTs in the literature, which may easily facilitate confirmatory results.

References

- Mattei J, Qi Q, Hu FB, Sacks FM, Qi L. TCF7L2 genetic variants modulate the effect of dietary fat intake on changes in body composition during a weight-loss intervention. *Am J Clin Nutr* 2012;96:1129–36.
- Haupt A, Thamer C, Heni M, Ketterer C, Machann J, Schick F, et al. Gene variants of TCF7L2 influence weight loss and body composition during lifestyle intervention in a population at risk for type 2 diabetes. *Diabetes* 2010;59:747–50.
- Grau K, Cauchi S, Holst C, Astrup A, Martinez JA, Saris WH, et al. TCF7L2 rs7903146-macronutrient interaction in obese individuals' responses to a 10-wk randomized hypoenergetic diet. *Am J Clin Nutr* 2010;91:472–9.
- Xiang L, Wu H, Pan A, Patel B, Xiang G, Qi L, et al. FTO genotype and weight loss in diet and lifestyle interventions: a systematic review and meta-analysis. *Am J Clin Nutr* 2016;103:1162–70.
- Cameron JD, Riou MÈ, Tesson F, Goldfield GS, Rabasa-Lhoret R, Brochu M, et al. The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women. *Appetite* 2013;60:111–6.
- Roth CL, Hinney A, Schur EA, Elfers CT, Reinehr T. Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention. *BMC Pediatr* 2013;13, 197 <https://doi.org/10.1186/1471-2431-13-197>.
- Schüler R, Osterhoff MA, Frahnov T, Möhlig M, Spranger J, Stefanovski D, et al. Dietary fat intake modulates effects of a frequent ACE gene variant on glucose tolerance with association to type 2 diabetes. *Sci Rep* 2017;7:9234.
- Chamberlain AM, Schreiner PJ, Fornage M, Loria CM, Siscovick D, Boerwinkle E. Ala54Thr polymorphism of the fatty acid binding protein 2 gene and saturated fat intake in relation to lipid levels and insulin resistance: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Metabolism* 2009;58:1222–8.
- Reinehr T, Friedel S, Mueller TD, Toschke AM, Hebebrand J, Hinney A. Evidence for an influence of TCF7L2 polymorphism rs7903146 on insulin resistance and sensitivity indices in overweight children and adolescents during a lifestyle intervention. *Int J Obes* 2008;32:1521–4.
- Schüler R, Osterhoff MA, Frahnov T, Seltmann AC, Busjahn A, Kabisch S, et al. High-saturated-fat diet increases circulating angiotensin-converting enzyme, which is

Editorial to: Role of rs670 variant of APOA1 gene on metabolic response after a high fat vs. a low fat hypocaloric diets in obese human subjects

Duality of interest: SK received travel grants (including conference fees and accommodation) from Rettenmaier & Soehne, Holzmuehle, Germany, Sanofi, Eli Lilly. His current projects are funded by the Federal Ministry of Education and Research/German Center for Diabetes Research (DZD) and are supported by the California Walnut Commission. The author declares no further conflicts of interest associated with this manuscript. The sponsors were neither involved in study design, data collection nor publication.

- enhanced by the rs4343 polymorphism defining persons at risk of nutrient-dependent increases of blood pressure. *J Am Heart Assoc* 2017;6.
11. Jerončić I, Mulić R, Klismanić Z, Rudan D, Boban M, Zgaga L. Interactions between genetic variants in glucose transporter type 9 (SLC2A9) and dietary habits in serum uric acid regulation. *Croat Med J* 2010;51:40-7.
 12. Božina T, Lovrić J, Šimičević L, Merkle A, Božina M, Jelaković B, et al. Can the choice of diet undermine the potential genetic risk of AT1R 1166A>C gene polymorphism? *Gene* 2018;679:291-6.
 13. Kim M, Chae JS, Kim M, Lee SH, Lee JH. Effects of a 3-year dietary intervention on age-related changes in triglyceride and apolipoprotein A-V levels in patients with impaired fasting glucose or new-onset type 2 diabetes as a function of the APOA5-1131 T>C polymorphism. *Nutr J* 2014;13:40.
 14. Pishva H, Mahboob SA, Mehdipour P, Eshraghian MR, Mohammadi-Asl J, Hosseini S, et al. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects. *Nutrition* 2010;26:1117-21.
 15. McColley SP, Georgopoulos A, Young LR, Kurzer MS, Redmon JB, Raatz SK. A high-fat diet and the threonine-encoding allele (Thr54) polymorphism of fatty acid-binding protein 2 reduce plasma triglyceride-rich lipoproteins. *Nutr Res* 2011;31:503-8.
 16. Salto LM, Bu L, Beeson WL, Firek A, Cordero-MacIntyre Z, De Leon M. The Ala54Thr polymorphism of the fatty acid binding protein 2 gene modulates HDL cholesterol in Mexican-Americans with type 2 diabetes. *Int J Environ Res Public Health* 2015;13.
 17. Cabré A, Babio N, Lázaro I, Bulló M, Garcia-Arellano A, Masana L, et al. FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. *Atherosclerosis* 2012;222:229-34.
 18. Almeida JC, Gross JL, Canani LH, Zelmanovitz T, Perassolo MS, Azevedo MJ. The Ala54Thr polymorphism of the FABP2 gene influences the postprandial fatty acids in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2010;95:3909-17.
 19. Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Goni L, Cuervo M, Martinez JA. Association of the Gly482Ser PPARG1A gene variant with different cholesterol outcomes in response to two energy-restricted diets in subjects with excessive weight. *Nutrition* 2018;47:83-9.
 20. Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Goni L, Cuervo M, Martinez JA. Differential lipid metabolism outcomes associated with ADRB2 gene polymorphisms in response to two dietary interventions in overweight/obese subjects. *Nutr Metab Cardiovasc Dis* 2018;28:165-72.
 21. MacKay DS, Eck PK, Gebauer SK, Baer DJ, Jones PJ. CYP7A1-rs3808607 and APOE isoform associate with LDL cholesterol lowering after plant sterol consumption in a randomized clinical trial. *Am J Clin Nutr* 2015;102:951-7.
 22. Schüler R, Seebeck N, Osterhoff MA, Witte V, Flöel A, Busjahn A, et al. VEGF and GLUT1 are highly heritable, inversely correlated and affected by dietary fat intake: consequences for cognitive function in humans. *Mol Metab* 2018;11:129-36.
 23. Corella D, Ramírez-Sabio JB, Coltell O, Ortega-Azorín C, Estruch R, Martínez-González MA, et al. Effects of the Ser326Cys polymorphism in the DNA repair OGG1 gene on cancer, cardiovascular, and all-cause mortality in the PREDIMED study: modulation by diet. *J Acad Nutr Diet* 2018;118:589-605.

Stefan Kabisch

*Department of Clinical Nutrition, German Institute of Human Nutrition
Potsdam-Rehbrücke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal
Germany*

*German Center for Diabetes Research (Deutsches Zentrum für
Diabetesforschung e.V.; DZD), Geschäftsstelle am Helmholtz-Zentrum
München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany
E-mail address: Stefan.kabisch@dife.de*